eligibility_summary
Eligibility: Locally advanced/metastatic cancer with KRAS G12D confirmed by CLIA-certified (or equivalent) testing. Part 1: advanced solid tumors after ≥1 prior systemic therapy with evaluable or measurable disease, Parts 2–3: measurable per RECIST 1.1. ECOG 0–1 and adequate organ function. Exclude prior KRAS inhibitor, active brain mets/meningitis, other malignancy <2 yrs, significant cardiovascular disease, or other safety risks. Other criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions: QTX3034—investigational small‑molecule targeted therapy intended to inhibit KRAS G12D, tested alone or with cetuximab—an anti‑EGFR chimeric monoclonal antibody (biologic). Mechanisms: QTX3034 directly blocks mutant KRAS G12D, aiming to suppress downstream RAS‑MAPK signaling (RAF‑MEK‑ERK) that drives tumor growth. Cetuximab inhibits EGFR ligand binding and receptor activation, reducing upstream KRAS signaling and can engage immune effector functions (ADCC). Cells/pathways targeted: KRAS G12D–mutant tumor cells in solid tumors, EGFR‑dependent epithelial tumor cells, key pathways include EGFR→KRAS→RAF/MEK/ERK.